SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
Recruiting · NCT07096999 · Observational (researchers observe without assigning treatment) · Lead sponsor: University of Michigan Rogel Cancer Center
View the official record on ClinicalTrials.gov →Interventions studied
Non-Interventional Study
What this trial is about
This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy
Who can take part
Age range
18 Years and older
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- \* 177Lu-617 PSMA treatment scheduled for mCRPC
- Clinically stable as determined by the nuclear medicine clinicians
- Male
- ≥ 18 years of age
- Willing and able to provide informed consent
Exclusion criteria
- Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed
Where it is running
1 location listed across 1 US state.
- University of Michigan Comprehensive Cancer Center - Ann Arbor, Michigan, United States